Copyright Reports & Markets. All rights reserved.

Global Primary Immunodeficiency Therapeutic Market 2025 by Company, Regions, Type and Application, Forecast to 2031

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Primary Immunodeficiency Therapeutic by Type
    • 1.3.1 Overview: Global Primary Immunodeficiency Therapeutic Market Size by Type: 2020 Versus 2024 Versus 2031
    • 1.3.2 Global Primary Immunodeficiency Therapeutic Consumption Value Market Share by Type in 2024
    • 1.3.3 Immunoglobulin Replacement Therapy
    • 1.3.4 Stem Cell or Bone Marrow Transplantation
    • 1.3.5 Antibiotic Therapy
    • 1.3.6 Gene Therapy
    • 1.3.7 Others
  • 1.4 Global Primary Immunodeficiency Therapeutic Market by Application
    • 1.4.1 Overview: Global Primary Immunodeficiency Therapeutic Market Size by Application: 2020 Versus 2024 Versus 2031
    • 1.4.2 Antibody Deficiency
    • 1.4.3 Cellular Immunodeficiency
    • 1.4.4 Innate Immune Disorders
    • 1.4.5 Others
  • 1.5 Global Primary Immunodeficiency Therapeutic Market Size & Forecast
  • 1.6 Global Primary Immunodeficiency Therapeutic Market Size and Forecast by Region
    • 1.6.1 Global Primary Immunodeficiency Therapeutic Market Size by Region: 2020 VS 2024 VS 2031
    • 1.6.2 Global Primary Immunodeficiency Therapeutic Market Size by Region, (2020-2031)
    • 1.6.3 North America Primary Immunodeficiency Therapeutic Market Size and Prospect (2020-2031)
    • 1.6.4 Europe Primary Immunodeficiency Therapeutic Market Size and Prospect (2020-2031)
    • 1.6.5 Asia-Pacific Primary Immunodeficiency Therapeutic Market Size and Prospect (2020-2031)
    • 1.6.6 South America Primary Immunodeficiency Therapeutic Market Size and Prospect (2020-2031)
    • 1.6.7 Middle East & Africa Primary Immunodeficiency Therapeutic Market Size and Prospect (2020-2031)

2 Company Profiles

  • 2.1 Baxter International
    • 2.1.1 Baxter International Details
    • 2.1.2 Baxter International Major Business
    • 2.1.3 Baxter International Primary Immunodeficiency Therapeutic Product and Solutions
    • 2.1.4 Baxter International Primary Immunodeficiency Therapeutic Revenue, Gross Margin and Market Share (2020-2025)
    • 2.1.5 Baxter International Recent Developments and Future Plans
  • 2.2 Takeda Pharmaceutical
    • 2.2.1 Takeda Pharmaceutical Details
    • 2.2.2 Takeda Pharmaceutical Major Business
    • 2.2.3 Takeda Pharmaceutical Primary Immunodeficiency Therapeutic Product and Solutions
    • 2.2.4 Takeda Pharmaceutical Primary Immunodeficiency Therapeutic Revenue, Gross Margin and Market Share (2020-2025)
    • 2.2.5 Takeda Pharmaceutical Recent Developments and Future Plans
  • 2.3 CSL Limited
    • 2.3.1 CSL Limited Details
    • 2.3.2 CSL Limited Major Business
    • 2.3.3 CSL Limited Primary Immunodeficiency Therapeutic Product and Solutions
    • 2.3.4 CSL Limited Primary Immunodeficiency Therapeutic Revenue, Gross Margin and Market Share (2020-2025)
    • 2.3.5 CSL Limited Recent Developments and Future Plans
  • 2.4 Octapharma
    • 2.4.1 Octapharma Details
    • 2.4.2 Octapharma Major Business
    • 2.4.3 Octapharma Primary Immunodeficiency Therapeutic Product and Solutions
    • 2.4.4 Octapharma Primary Immunodeficiency Therapeutic Revenue, Gross Margin and Market Share (2020-2025)
    • 2.4.5 Octapharma Recent Developments and Future Plans
  • 2.5 Kedrion Biopharma
    • 2.5.1 Kedrion Biopharma Details
    • 2.5.2 Kedrion Biopharma Major Business
    • 2.5.3 Kedrion Biopharma Primary Immunodeficiency Therapeutic Product and Solutions
    • 2.5.4 Kedrion Biopharma Primary Immunodeficiency Therapeutic Revenue, Gross Margin and Market Share (2020-2025)
    • 2.5.5 Kedrion Biopharma Recent Developments and Future Plans
  • 2.6 Bio Products Laboratory
    • 2.6.1 Bio Products Laboratory Details
    • 2.6.2 Bio Products Laboratory Major Business
    • 2.6.3 Bio Products Laboratory Primary Immunodeficiency Therapeutic Product and Solutions
    • 2.6.4 Bio Products Laboratory Primary Immunodeficiency Therapeutic Revenue, Gross Margin and Market Share (2020-2025)
    • 2.6.5 Bio Products Laboratory Recent Developments and Future Plans
  • 2.7 LFB group
    • 2.7.1 LFB group Details
    • 2.7.2 LFB group Major Business
    • 2.7.3 LFB group Primary Immunodeficiency Therapeutic Product and Solutions
    • 2.7.4 LFB group Primary Immunodeficiency Therapeutic Revenue, Gross Margin and Market Share (2020-2025)
    • 2.7.5 LFB group Recent Developments and Future Plans
  • 2.8 Grifols
    • 2.8.1 Grifols Details
    • 2.8.2 Grifols Major Business
    • 2.8.3 Grifols Primary Immunodeficiency Therapeutic Product and Solutions
    • 2.8.4 Grifols Primary Immunodeficiency Therapeutic Revenue, Gross Margin and Market Share (2020-2025)
    • 2.8.5 Grifols Recent Developments and Future Plans
  • 2.9 Lupin Pharmaceuticals
    • 2.9.1 Lupin Pharmaceuticals Details
    • 2.9.2 Lupin Pharmaceuticals Major Business
    • 2.9.3 Lupin Pharmaceuticals Primary Immunodeficiency Therapeutic Product and Solutions
    • 2.9.4 Lupin Pharmaceuticals Primary Immunodeficiency Therapeutic Revenue, Gross Margin and Market Share (2020-2025)
    • 2.9.5 Lupin Pharmaceuticals Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Primary Immunodeficiency Therapeutic Revenue and Share by Players (2020-2025)
  • 3.2 Market Share Analysis (2024)
    • 3.2.1 Market Share of Primary Immunodeficiency Therapeutic by Company Revenue
    • 3.2.2 Top 3 Primary Immunodeficiency Therapeutic Players Market Share in 2024
    • 3.2.3 Top 6 Primary Immunodeficiency Therapeutic Players Market Share in 2024
  • 3.3 Primary Immunodeficiency Therapeutic Market: Overall Company Footprint Analysis
    • 3.3.1 Primary Immunodeficiency Therapeutic Market: Region Footprint
    • 3.3.2 Primary Immunodeficiency Therapeutic Market: Company Product Type Footprint
    • 3.3.3 Primary Immunodeficiency Therapeutic Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Primary Immunodeficiency Therapeutic Consumption Value and Market Share by Type (2020-2025)
  • 4.2 Global Primary Immunodeficiency Therapeutic Market Forecast by Type (2026-2031)

5 Market Size Segment by Application

  • 5.1 Global Primary Immunodeficiency Therapeutic Consumption Value Market Share by Application (2020-2025)
  • 5.2 Global Primary Immunodeficiency Therapeutic Market Forecast by Application (2026-2031)

6 North America

  • 6.1 North America Primary Immunodeficiency Therapeutic Consumption Value by Type (2020-2031)
  • 6.2 North America Primary Immunodeficiency Therapeutic Market Size by Application (2020-2031)
  • 6.3 North America Primary Immunodeficiency Therapeutic Market Size by Country
    • 6.3.1 North America Primary Immunodeficiency Therapeutic Consumption Value by Country (2020-2031)
    • 6.3.2 United States Primary Immunodeficiency Therapeutic Market Size and Forecast (2020-2031)
    • 6.3.3 Canada Primary Immunodeficiency Therapeutic Market Size and Forecast (2020-2031)
    • 6.3.4 Mexico Primary Immunodeficiency Therapeutic Market Size and Forecast (2020-2031)

7 Europe

  • 7.1 Europe Primary Immunodeficiency Therapeutic Consumption Value by Type (2020-2031)
  • 7.2 Europe Primary Immunodeficiency Therapeutic Consumption Value by Application (2020-2031)
  • 7.3 Europe Primary Immunodeficiency Therapeutic Market Size by Country
    • 7.3.1 Europe Primary Immunodeficiency Therapeutic Consumption Value by Country (2020-2031)
    • 7.3.2 Germany Primary Immunodeficiency Therapeutic Market Size and Forecast (2020-2031)
    • 7.3.3 France Primary Immunodeficiency Therapeutic Market Size and Forecast (2020-2031)
    • 7.3.4 United Kingdom Primary Immunodeficiency Therapeutic Market Size and Forecast (2020-2031)
    • 7.3.5 Russia Primary Immunodeficiency Therapeutic Market Size and Forecast (2020-2031)
    • 7.3.6 Italy Primary Immunodeficiency Therapeutic Market Size and Forecast (2020-2031)

8 Asia-Pacific

  • 8.1 Asia-Pacific Primary Immunodeficiency Therapeutic Consumption Value by Type (2020-2031)
  • 8.2 Asia-Pacific Primary Immunodeficiency Therapeutic Consumption Value by Application (2020-2031)
  • 8.3 Asia-Pacific Primary Immunodeficiency Therapeutic Market Size by Region
    • 8.3.1 Asia-Pacific Primary Immunodeficiency Therapeutic Consumption Value by Region (2020-2031)
    • 8.3.2 China Primary Immunodeficiency Therapeutic Market Size and Forecast (2020-2031)
    • 8.3.3 Japan Primary Immunodeficiency Therapeutic Market Size and Forecast (2020-2031)
    • 8.3.4 South Korea Primary Immunodeficiency Therapeutic Market Size and Forecast (2020-2031)
    • 8.3.5 India Primary Immunodeficiency Therapeutic Market Size and Forecast (2020-2031)
    • 8.3.6 Southeast Asia Primary Immunodeficiency Therapeutic Market Size and Forecast (2020-2031)
    • 8.3.7 Australia Primary Immunodeficiency Therapeutic Market Size and Forecast (2020-2031)

9 South America

  • 9.1 South America Primary Immunodeficiency Therapeutic Consumption Value by Type (2020-2031)
  • 9.2 South America Primary Immunodeficiency Therapeutic Consumption Value by Application (2020-2031)
  • 9.3 South America Primary Immunodeficiency Therapeutic Market Size by Country
    • 9.3.1 South America Primary Immunodeficiency Therapeutic Consumption Value by Country (2020-2031)
    • 9.3.2 Brazil Primary Immunodeficiency Therapeutic Market Size and Forecast (2020-2031)
    • 9.3.3 Argentina Primary Immunodeficiency Therapeutic Market Size and Forecast (2020-2031)

10 Middle East & Africa

  • 10.1 Middle East & Africa Primary Immunodeficiency Therapeutic Consumption Value by Type (2020-2031)
  • 10.2 Middle East & Africa Primary Immunodeficiency Therapeutic Consumption Value by Application (2020-2031)
  • 10.3 Middle East & Africa Primary Immunodeficiency Therapeutic Market Size by Country
    • 10.3.1 Middle East & Africa Primary Immunodeficiency Therapeutic Consumption Value by Country (2020-2031)
    • 10.3.2 Turkey Primary Immunodeficiency Therapeutic Market Size and Forecast (2020-2031)
    • 10.3.3 Saudi Arabia Primary Immunodeficiency Therapeutic Market Size and Forecast (2020-2031)
    • 10.3.4 UAE Primary Immunodeficiency Therapeutic Market Size and Forecast (2020-2031)

11 Market Dynamics

  • 11.1 Primary Immunodeficiency Therapeutic Market Drivers
  • 11.2 Primary Immunodeficiency Therapeutic Market Restraints
  • 11.3 Primary Immunodeficiency Therapeutic Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 Primary Immunodeficiency Therapeutic Industry Chain
  • 12.2 Primary Immunodeficiency Therapeutic Upstream Analysis
  • 12.3 Primary Immunodeficiency Therapeutic Midstream Analysis
  • 12.4 Primary Immunodeficiency Therapeutic Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Primary Immunodeficiency Therapeutic market size was valued at US$ 522 million in 2024 and is forecast to a readjusted size of USD 755 million by 2031 with a CAGR of 5.5% during review period.
    Primary immunodeficiencies are a group of different disorders in which part of the body"s immune system (mainly cells and proteins) is missing or does not function normally. As per researchers, estimated more than 300 different kinds of primary immunodeficiency disease (PIDD). The immune system is composed of white blood cells made in the bone marrow which protect and defend against attacks by foreign invaders such as bacteria, fungi, and germs. Antibodies and Complement are proteins that are made in response to infection or immunization and helps to fight against infections and plays a protective role in the immune system. In the most common primary immunodeficiency diseases, different forms of cells or proteins are missing or do not function which results in severe infections and/or infections that are unusually hard to cure. These infections may attack the respiratory system, the brain or spinal cord, the ears, skin, or in the urinary or gastrointestinal tracts. In some instances, primary immunodeficiency diseases target specific and/or multiple organs, glands, cells, and tissues. For example, heart defects are present in some primary immunodeficiency diseases.
    The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
    This report is a detailed and comprehensive analysis for global Primary Immunodeficiency Therapeutic market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Primary Immunodeficiency Therapeutic market size and forecasts, in consumption value ($ Million), 2020-2031
    Global Primary Immunodeficiency Therapeutic market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
    Global Primary Immunodeficiency Therapeutic market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
    Global Primary Immunodeficiency Therapeutic market shares of main players, in revenue ($ Million), 2020-2025
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Primary Immunodeficiency Therapeutic
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Primary Immunodeficiency Therapeutic market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Baxter International, Takeda Pharmaceutical, CSL Limited, Octapharma, Kedrion Biopharma, Bio Products Laboratory, LFB group, Grifols, Lupin Pharmaceuticals, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market segmentation
    Primary Immunodeficiency Therapeutic market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Immunoglobulin Replacement Therapy
    Stem Cell or Bone Marrow Transplantation
    Antibiotic Therapy
    Gene Therapy
    Others
    Market segment by Application
    Antibody Deficiency
    Cellular Immunodeficiency
    Innate Immune Disorders
    Others
    Market segment by players, this report covers
    Baxter International
    Takeda Pharmaceutical
    CSL Limited
    Octapharma
    Kedrion Biopharma
    Bio Products Laboratory
    LFB group
    Grifols
    Lupin Pharmaceuticals
    Market segment by regions, regional analysis covers
    North America (United States, Canada and Mexico)
    Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
    South America (Brazil, Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 13 chapters:
    Chapter 1, to describe Primary Immunodeficiency Therapeutic product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top players of Primary Immunodeficiency Therapeutic, with revenue, gross margin, and global market share of Primary Immunodeficiency Therapeutic from 2020 to 2025.
    Chapter 3, the Primary Immunodeficiency Therapeutic competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
    Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
    Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Primary Immunodeficiency Therapeutic market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
    Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
    Chapter 12, the key raw materials and key suppliers, and industry chain of Primary Immunodeficiency Therapeutic.
    Chapter 13, to describe Primary Immunodeficiency Therapeutic research findings and conclusion.

    Buy now